The postMONARCH study, a phase 3, randomized, placebo-controlled trial, demonstrated that switching to abemaciclib plus fulvestrant significantly reduced the risk of disease progression in HR+, HER2− advanced breast cancer with progression on prior CDK4/6i plus endocrine therapy. This evidence concerns the gene ERBB2 and breast carcinoma.